FDA issued a complete response letter for Summit’s ivonescimab in EGFR mutated lung cancer, disclosed Nov 15, 2026, citing no statistically significant OS gain.
Last updated: November 15, 2026
FDA declined to approve Summit Therapeutics’ ivonescimab plus chemotherapy for EGFR mutated non squamous lung cancer after EGFR TKI therapy. Per Summit, the agency said a progression free survival win without a statistically significant overall survival improvement did not establish effectiveness.
Scope: the HARMONi biologics license application, what FDA said according to Summit, the data behind it, and what it signals for oncology sponsors running trials with survival as a primary endpoint.
What did FDA decide on ivonescimab?
FDA issued a complete response letter (CRL), meaning it will not approve the application in its present form. Summit disclosed the letter in a release dated Sunday, November 15, 2026, one day after the November 14 PDUFA goal date it announced when the BLA was accepted in January.
The application sought approval of ivonescimab, a PD-1 and VEGF bispecific antibody, with platinum doublet chemotherapy in locally advanced or metastatic non squamous non small cell lung cancer (NSCLC) with an EGFR mutation, after progression on a third generation EGFR tyrosine kinase inhibitor. It was based on HARMONi, a global randomized, double blind Phase III trial against placebo plus chemotherapy. Summit partners with Akeso on the drug, which has been approved in China since May 2024.
Why did FDA reject the HARMONi application?
Per Summit’s release, the CRL says substantial evidence of effectiveness was not established in the absence of a statistically significant overall survival (OS) improvement, and that a progression free survival (PFS) benefit without a statistically significant OS benefit does not support a positive benefit risk profile. HARMONi had two primary endpoints, PFS and OS. It met one.
That is the important part for the industry. FDA did not cite manufacturing, safety signals or data integrity in anything Summit disclosed. The problem is the evidence package itself. Under FDA’s September 2025 policy of releasing CRLs promptly after issuance, the letter should eventually appear in the openFDA database, which will show whether Summit’s summary is complete. Our complete response letter explainer covers what the letter must contain and the sponsor’s options.
What did the HARMONi trial show?
HARMONi randomized 438 patients, 219 per arm, at 114 sites across Asia, Europe and North America. Ivonescimab plus chemotherapy cut the risk of progression or death by 48% (PFS HR 0.52). Overall survival at the primary analysis trended the same way but missed significance, with a hazard ratio of 0.79 and p=0.057.
| Endpoint (primary analysis) | Ivonescimab plus chemo | Placebo plus chemo | Hazard ratio (95% CI) | Result |
|---|---|---|---|---|
| Median PFS (independent review) | 6.8 months | 4.4 months | 0.52 (0.41 to 0.66), p<0.0001 | Met |
| Median OS (April 2025 cut) | 16.8 months | 14.0 months | 0.79 (0.62 to 1.01), p=0.057 | Not significant |
| Discontinuation for treatment related AEs | 16 (7.3%) | 11 (5.0%) | n/a | Per Summit |
| Deaths from treatment related AEs | 4 (1.8%) | 5 (2.3%) | n/a | Per Summit |
Sources: Summit releases of August 25, 2026 (Lancet Oncology publication) and November 15, 2026. Table compiled by BioMed Nexus.
The medians work out to a 2.4 month PFS gain and a 2.8 month OS gap (our arithmetic). Summit reported no new safety signals.
Did the later overall survival data help?
Not enough for FDA. Summit kept updating OS as Western patients matured, and the hazard ratio improved with each cut. But the later analyses were described as nominal or post hoc. Our read: under standard multiplicity rules, a primary endpoint that missed at its planned analysis is not rescued by later looks. The letter, as Summit describes it, reads exactly that way.
| OS data cut | Full population HR | Western subgroup HR | Western median follow up | Status |
|---|---|---|---|---|
| April 2025 (primary) | 0.79 (0.62 to 1.01) | 0.98 | 9.2 months | p=0.057, not significant |
| September 2025 | 0.78 (0.62 to 0.98) | 0.84 | 13.7 months | Nominal p=0.0332 |
| June 2026 | 0.76 | 0.76 | 23.2 months | Post hoc per Summit |
Source: Summit releases of July 22, 2026 and November 15, 2026. Asian median follow up was 32.7 months at the later cuts.
Western patients were 165 of 438 enrolled, about 38% (our arithmetic). At the primary cut, their follow up was shorter than the median survival itself, which is the argument Summit made for waiting. FDA was not persuaded.
What did Summit say it will do next?
Summit did not announce a resubmission plan, a meeting request with FDA or a new trial in its release. Chairman and co chief executive Robert W. Duggan said the company was “disappointed for patients and their families awaiting additional treatment options in this setting,” and that, with five positive Phase III studies between Summit and Akeso, nothing changes about its belief in ivonescimab.
The development program continues: HARMONi-3 in first line NSCLC, HARMONi-7, HARMONi-GI3 in colorectal cancer, HARMONi-GU1 in urothelial cancer, a renal cell carcinoma study, a GORTEC head and neck study and the ECOG-ACRIN biliary study EA2251, plus collaborations with AstraZeneca, Daiichi Sankyo, Revolution Medicines, GSK and Arcus. Monday, November 16, is the first trading session after the disclosure; we have no verified stock reaction yet.
What does the ivonescimab CRL mean for other sponsors?
Our read: when OS is a named primary endpoint and misses, a strong PFS result and later supportive survival cuts may not carry an approval, even in a setting with few options. Sponsors who split alpha between PFS and OS are now on notice that FDA will hold them to the OS half when the benefit risk case leans on it.
It also raises the bar for the PD-1 and VEGF bispecific class in the US. The pitch for these drugs is that they can beat checkpoint inhibitors or add to chemotherapy where PD-1 drugs failed. HARMONi was meant to prove that in a Western heavy population. China’s data, where Summit says HARMONi-A showed a statistically significant OS benefit, do not substitute for a US label.
Our checklist for oncology sponsors after the HARMONi CRL
- If OS is a primary endpoint, power it for the region mix you will file on, not the global mix.
- Agree with FDA up front on when OS is analyzed and what follow up counts as mature.
- Treat later survival cuts as supportive only; do not build a filing on them.
- Plan disclosure assuming the CRL text becomes public under FDA’s publication policy.
- Reset milestone, royalty and financing models tied to the original PDUFA date.
What to watch next
- Summit’s first trading session on Monday, November 16, and any investor call or follow up filing.
- Publication of the actual CRL text in FDA’s openFDA dataset.
- Any statement from Summit on a meeting with FDA or a path to resubmission.
- HARMONi-3 in first line NSCLC, now the most important US program for the drug.
FAQ
Did FDA approve ivonescimab?
No. FDA issued a complete response letter for the HARMONi based BLA in EGFR mutated non squamous NSCLC after EGFR TKI therapy, which Summit disclosed on November 15, 2026.
Why was ivonescimab rejected?
Per Summit, FDA said effectiveness was not established without a statistically significant overall survival improvement, and a PFS benefit alone did not support a positive benefit risk profile.
What is ivonescimab?
A bispecific antibody that targets PD-1 and VEGF. Summit develops it with partner Akeso, and it has been approved in China since May 2024.
What did HARMONi show?
Median PFS of 6.8 versus 4.4 months (HR 0.52) and median OS of 16.8 versus 14.0 months (HR 0.79, p=0.057) at the primary analysis.
Was the PDUFA date November 14, 2026?
Yes. Summit said in January 2026 that FDA accepted the BLA with a goal date of November 14, 2026. Summit’s CRL release is dated November 15.
Did FDA cite safety or manufacturing problems?
Summit’s release did not mention any. It reported treatment related death rates of 1.8% on ivonescimab versus 2.3% on chemotherapy alone.
Can Summit resubmit?
Under 21 CFR 601.3 a BLA sponsor can resubmit or withdraw after a CRL and has one year to act, with extensions available. Summit has not announced a plan.
Will the CRL be made public?
FDA said in September 2025 that it will release future CRLs promptly after they are issued, redacted for confidential information, through openFDA.
Does this affect other ivonescimab trials?
The CRL covers only this indication. Summit says HARMONi-3 and its other trials continue.
Sources
- Summit Therapeutics, “Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application,” November 15, 2026. Primary.
- Summit Therapeutics, HARMONi updated OS release, July 22, 2026. Primary.
- Summit Therapeutics, HARMONi Lancet Oncology publication release, August 25, 2026. Primary.
- Summit Therapeutics BLA submission (January 12, 2026) and FDA acceptance (January 29, 2026) releases, filed with the SEC. Primary.
- FDA, real time release of complete response letters, September 4, 2025. Primary.
- 21 CFR 601.3 (govinfo). Primary.
Related coverage
- What is an FDA complete response letter? CRLs explained
- PDUFA date explained: goal dates, extensions and FDA decisions
- FDA approves Imfinzi plus Padcev for cisplatin ineligible MIBC
- What is Project Orbis? How FDA shares cancer drug reviews
- FDA accelerated approval: confirmatory trial rules explained
- BioMed Nexus directory
Get the daily briefing on FDA decisions and industry moves: subscribe to BioMed Nexus.


